60%-HFD, 10%-CD |
16 weeks |
C57BL/6 |
increased reactive oxygen species (ROS); decreased cognition |
[43] |
60%-HFD, 5%-CD |
16 weeks |
C57BL/6 |
increased IR, ROS; no AD histopathology, no increase in Aβ or phospho-tau, no impairments in IGF signaling or acetylcholine homeostasis |
[33] |
10% sucrose in water |
25 weeks |
B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J |
Metabolic dysfunction, memory impairment, increased apoE and aggregation of Aβ in the brain |
[34] |
40%-WD, 10%-CD |
4 weeks |
APPswe/PS1M146V; PS1M146V; C57BL/6 |
increased cerebral ROS, alterations in brain Aβ |
[36] |
60%-HFD |
16 weeks |
C57BL/6 |
impairment of fear-conditioning test |
[53] |
60%-HFD, 10%-CD |
20 weeks |
APPSwe/Ind
|
metabolic dysfunction; decreased cognition |
[54] |
21.2%-HFD, 5.5%-CD |
22 weeks |
C57BL/6 |
increased pro-inflammatory factors and APP expression in brains and fat tissues |
[55] |
55% -HFD |
8 weeks |
WT, PSEN1, APP/PSEN1 |
AD increases body weight gain, glucose intolerance and insulin resistance induced by HFD in mice |
[56] |
60%-HFD |
20 weeks |
C57BL/6J, MC4R−/−, Tie2-GFP |
enhanced GFAP-immunoreactivity in the medial preoptic, paraventricular and dorsomedial nuclei of the hypothalamus. |
[57] |
60%-HFD |
22 weeks |
C57BL/6 |
impaired hippocampus-dependent spatial memory, alteration in the expression of corresponding genes |
[58] |
58%-HFD, 10.5%-CD |
12 weeks |
C57BL/6 |
promotion of negative emotional states and depressive-like symptomology |
[59] |
45%-HFD, 10%-CD |
14 weeks |
C57BL/6 |
HFD selectively protects against the effects of chronic social stress in the mouse |
[60] |